Boston Scientific (NYSE:BSX) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• Boston Scientific has been downgraded from a "buy" to a "hold" rating by Wall Street Zen, reflecting a cautious outlook from analysts.
• Despite the downgrade, several firms including Barclays and Wells Fargo have increased their price targets for the company's stock, indicating continued investment interest.
• The company reported strong earnings, with $0.75 per share, surpassing expectations, and a year-over-year revenue increase of 22.8% to $5.06 billion.

Boston Scientific (NYSE:BSX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Friday.

Several other analysts have also recently commented on the stock. Barclays boosted their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research note on Thursday. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Raymond James Financial boosted their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Finally, Leerink Partners boosted their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an "outperform" rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $120.79.

Boston Scientific Price Performance

Shares of BSX traded up $1.08 during trading hours on Friday, reaching $97.30. 10,767,469 shares of the stock traded hands, compared to its average volume of 11,930,494. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific has a 52-week low of $80.64 and a 52-week high of $109.50. The company's 50-day moving average price is $102.93 and its two-hundred day moving average price is $102.05. The company has a market cap of $144.17 billion, a P/E ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the previous year, the company earned $0.62 EPS. Boston Scientific's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $17,972,457 over the last 90 days. 0.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of BSX. 1248 Management LLC purchased a new stake in Boston Scientific during the first quarter valued at approximately $26,000. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter valued at approximately $26,000. Y.D. More Investments Ltd purchased a new stake in Boston Scientific during the first quarter valued at approximately $27,000. Sound Income Strategies LLC lifted its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 120 shares during the last quarter. Finally, Kilter Group LLC purchased a new stake in Boston Scientific during the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.